Current Report Filing (8-k)
March 21 2019 - 2:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported)
March 20, 2019
|
|
LEXARIA BIOSCIENCE CORP.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
|
000-52138
|
|
20-2000871
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
100 – 740 McCurdy Road, Kelowna, BC Canada
|
|
V1X 2P7
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Registrant’s telephone number, including area code
(250) 765-6424
|
|
N/A
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
|
Item 1.02
Termination of a Material Definitive Agreement
|
On March 20, 2019 Lexaria BioScience Corp. (“Lexaria”) announced that the Definitive License Agreement entered into between Lexaria’s subsidiary, Lexaria CanPharm ULC, and NeutriSci International Inc. (“NeutriSci”), as originally announced on February 26, 2018, whereby NeutriSci was granted a license to Lexaria’s DehydraTECH
TM
, to produce tablets incorporating less than 0.3% tetrahydrocannabinol, has been terminated effective March 15, 2019.
|
Item 8.01
Other Events
|
|
On March 20, 2019 Lexaria announced the commencement its largest cannabinoid research program which will also include testing of Lexaria-designed nanotech enhancements to its current technology.
|
|
Item 9.01
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
LEXARIA BIOSCIENCE
CORP.
|
|
|
|
|
|
/s/ Chris Bunka
|
|
|
Chris Bunka
|
|
|
CEO, Principal Executive Officer
|
|
|
|
|
|
Date: March 21, 2019
|
|